Jill Broadfoot
Director of Finance/CFO bei ATYR PHARMA, INC.
Vermögen: 42 770 $ am 31.03.2024
Profil
Jill M.
Broadfoot currently works at Talphera, Inc., as Independent Director from 2021, Angiocrine Bioscience, Inc., as Director, and aTyr Pharma, Inc., as Chief Financial Officer from 2018.
Ms. Broadfoot also formerly worked at Otonomy, Inc., as Independent Director from 2021 to 2023, Medical Imaging Centers of America, Inc., as Divisional Controller in 1994, Vical, Inc., as Chief Financial Officer, Secretary & Senior VP from 2004 to 2013, DJO Global, Inc., as Vice President-Finance & Controller in 2004, Ernst & Young LLP, as Audit Manager from 1994 to 1999, GW Pharmaceuticals Ltd., as Vice President & Controller from 2016 to 2017, Emerald Health Pharmaceuticals, Inc., as Chief Financial Officer from 2017 to 2018, and Emerald Health Bioceuticals, Inc., as Chief Financial Officer from 2017 to 2018.
Ms. Broadfoot received her undergraduate degree in 1993 from San Diego State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ATYR PHARMA, INC.
0,03% | 01.03.2024 | 20 821 ( 0,03% ) | 40 601 $ | 31.03.2024 |
TALPHERA, INC.
0,01% | 10.10.2023 | 2 106 ( 0,01% ) | 2 169 $ | 31.03.2024 |
Aktive Positionen von Jill Broadfoot
| Unternehmen | Position | Beginn |
|---|---|---|
| ATYR PHARMA, INC. | Director of Finance/CFO | 30.07.2018 |
| TALPHERA, INC. | Director/Board Member | 20.11.2021 |
Angiocrine Bioscience, Inc.
 Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | Director/Board Member | - |
Ehemalige bekannte Positionen von Jill Broadfoot
| Unternehmen | Position | Ende |
|---|---|---|
| OTONOMY | Director/Board Member | 15.02.2023 |
Emerald Health Bioceuticals, Inc.
 Emerald Health Bioceuticals, Inc. BiotechnologyHealth Technology Emerald Health Bioceuticals, Inc. engages in the provision of research and development of cannabis-free nutritional supplements that support the body’s endocannabinoid system (ECS). Its products include Endo Omega, Endo OmegaVegan, Endo Immune, Endo Sleep, Endo Bliss, Endo Calm, Endo Inflame, and Endo Brain. The company was founded on March 27, 2015 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01.07.2018 |
Emerald Health Pharmaceuticals, Inc.
 Emerald Health Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Emerald Health Pharmaceuticals, Inc. engages in the development of medicines based on cannabinoid science. It focuses on discovering, developing, and commercializing proprietary cannabinoid-derived medicines. The company is headquartered in San Diego, CA. | Director of Finance/CFO | 01.07.2018 |
| GW PHARMACEUTICALS PLC | Comptroller/Controller/Auditor | 01.01.2017 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01.03.2013 |
Ausbildung von Jill Broadfoot
| San Diego State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| TALPHERA, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
| Medical Imaging Centers of America, Inc. | Health Services |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
DJO Global, Inc.
 DJO Global, Inc. Medical SpecialtiesHealth Technology DJO Global, Inc. engages in the development and distribution medical devices for musculoskeletal health, joint reconstruction, vascular health, and pain management. Its product include knee ligament bracing, custom bracing, post-op knee bracing, hip implants, shoulder implants, shoulder bracing, spine bracing, cervical collars, walking braces, and ankle bracing. The company was founded by Mark Nordquist and Ken Reed in 1978 and is headquartered in Lewisville, TX. | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Emerald Health Pharmaceuticals, Inc.
Emerald Health Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Emerald Health Pharmaceuticals, Inc. engages in the development of medicines based on cannabinoid science. It focuses on discovering, developing, and commercializing proprietary cannabinoid-derived medicines. The company is headquartered in San Diego, CA. | Health Technology |
GW Pharmaceuticals Ltd.
 GW Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology GW Pharmaceuticals Ltd. operates as an intermediate holding company and management company for investments in its subsidiaries. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Emerald Health Bioceuticals, Inc.
Emerald Health Bioceuticals, Inc. BiotechnologyHealth Technology Emerald Health Bioceuticals, Inc. engages in the provision of research and development of cannabis-free nutritional supplements that support the body’s endocannabinoid system (ECS). Its products include Endo Omega, Endo OmegaVegan, Endo Immune, Endo Sleep, Endo Bliss, Endo Calm, Endo Inflame, and Endo Brain. The company was founded on March 27, 2015 and is headquartered in San Diego, CA. | Health Technology |
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | Commercial Services |
